JP2014506928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506928A5 JP2014506928A5 JP2013556750A JP2013556750A JP2014506928A5 JP 2014506928 A5 JP2014506928 A5 JP 2014506928A5 JP 2013556750 A JP2013556750 A JP 2013556750A JP 2013556750 A JP2013556750 A JP 2013556750A JP 2014506928 A5 JP2014506928 A5 JP 2014506928A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- hormone releasing
- ileal brake
- brake hormone
- releasing compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 20
- 208000005176 Hepatitis C Diseases 0.000 claims description 11
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 10
- -1 asunapavir Chemical compound 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 20
- 229940088597 hormone Drugs 0.000 claims 17
- 239000005556 hormone Substances 0.000 claims 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 4
- 229960000517 boceprevir Drugs 0.000 claims 4
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 4
- ZVTDLPBHTSMEJZ-JSZLBQEHSA-N danoprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-JSZLBQEHSA-N 0.000 claims 4
- 235000021588 free fatty acids Nutrition 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- 229920003136 Eudragit® L polymer Polymers 0.000 claims 3
- 229920003137 Eudragit® S polymer Polymers 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 210000003405 ileum Anatomy 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- HLQXYDHLDZTWDW-KAWPREARSA-N (2r,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(pyrazol-1-ylmethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C([C@]1(C[C@@H]([C@@H](N1C(=O)C=1C=C(OC)C(=CC=1)C(C)(C)C)C=1SC=CN=1)COC)C(O)=O)N1C=CC=N1 HLQXYDHLDZTWDW-KAWPREARSA-N 0.000 claims 2
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 claims 2
- YFXGICNMLCGLHJ-RSKRLRQZSA-N 2,2-dimethylpropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound C1=CC=C2C(OP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC[C@H]3O[C@H]([C@]([C@@H]3O)(C)O)N3C=4N=C(N)N=C(C=4N=C3)OC)=CC=CC2=C1 YFXGICNMLCGLHJ-RSKRLRQZSA-N 0.000 claims 2
- PVRFQJIRERYGTQ-DSQUMVBZSA-N 9-[(2s,4ar,6r,7r,7ar)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine Chemical compound C([C@H]1O2)O[P@@](=O)(OC(C)C)O[C@H]1[C@](F)(C)[C@@H]2N1C(N=C(N)N=C2OCC)=C2N=C1 PVRFQJIRERYGTQ-DSQUMVBZSA-N 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 108010090287 SCY-635 Proteins 0.000 claims 2
- VKXWOLCNTHXCLF-DXEZIKHYSA-N [(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound CC(C)C(=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@](COC(=O)C(C)C)(N=[N+]=[N-])O[C@H]1N1C(=O)N=C(N)C=C1 VKXWOLCNTHXCLF-DXEZIKHYSA-N 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical group N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- WVROWPPEIMRGAB-UHFFFAOYSA-N bit225 Chemical compound C1=NN(C)C=C1C1=CC=CC2=CC(C(=O)NC(N)=N)=CC=C12 WVROWPPEIMRGAB-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229960005449 daclatasvir Drugs 0.000 claims 2
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- TTZHDVOVKQGIBA-IAAJYNJHSA-N propan-2-yl (2s)-2-[[[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)COP(=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IAAJYNJHSA-N 0.000 claims 2
- DEKOYVOWOVJMPM-RLHIPHHXSA-N setrobuvir Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(O)=C(C1=O)C=1NC2=CC=C(C=C2S(=O)(=O)N=1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 DEKOYVOWOVJMPM-RLHIPHHXSA-N 0.000 claims 2
- 229960002091 simeprevir Drugs 0.000 claims 2
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 claims 2
- 229960002063 sofosbuvir Drugs 0.000 claims 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- JXQUAHHUSMJUFV-HZPZRMRQSA-N 9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1([C@@H]2CCO[P@](O2)(=O)COCCN2C=3N=CN=C(C=3N=C2)N)=CC=CC(Cl)=C1 JXQUAHHUSMJUFV-HZPZRMRQSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical group NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims 1
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005338 clevudine Drugs 0.000 claims 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229940124828 glucokinase activator Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940097709 hepsera Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 claims 1
- 229960002480 nitazoxanide Drugs 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229950001452 pradefovir Drugs 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 1
- 229960004231 thymalfasin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 8
- 230000007882 cirrhosis Effects 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 5
- 208000010710 hepatitis C virus infection Diseases 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 241000711557 Hepacivirus Species 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940099268 synthroid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/932,633 | 2011-03-02 | ||
| US12/932,633 US9757346B2 (en) | 2008-09-03 | 2011-03-02 | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
| US201161480788P | 2011-04-29 | 2011-04-29 | |
| US61/480,788 | 2011-04-29 | ||
| US201161514174P | 2011-08-02 | 2011-08-02 | |
| US61/514,174 | 2011-08-02 | ||
| US201161551638P | 2011-10-26 | 2011-10-26 | |
| US61/551,638 | 2011-10-26 | ||
| PCT/US2012/026561 WO2012118712A2 (en) | 2011-03-02 | 2012-02-24 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017228965A Division JP2018065840A (ja) | 2011-03-02 | 2017-11-29 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506928A JP2014506928A (ja) | 2014-03-20 |
| JP2014506928A5 true JP2014506928A5 (https=) | 2015-04-02 |
| JP6253991B2 JP6253991B2 (ja) | 2017-12-27 |
Family
ID=46758432
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556750A Expired - Fee Related JP6253991B2 (ja) | 2011-03-02 | 2012-02-24 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP2017228965A Pending JP2018065840A (ja) | 2011-03-02 | 2017-11-29 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP2019033502A Pending JP2019123716A (ja) | 2011-03-02 | 2019-02-27 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017228965A Pending JP2018065840A (ja) | 2011-03-02 | 2017-11-29 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP2019033502A Pending JP2019123716A (ja) | 2011-03-02 | 2019-02-27 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9370528B2 (https=) |
| EP (1) | EP2680859B1 (https=) |
| JP (3) | JP6253991B2 (https=) |
| KR (4) | KR20200006177A (https=) |
| CN (2) | CN110152000A (https=) |
| AU (3) | AU2012223528A1 (https=) |
| BR (1) | BR112013022391A2 (https=) |
| EA (1) | EA201391262A1 (https=) |
| IL (2) | IL228259B (https=) |
| WO (1) | WO2012118712A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9155772B2 (en) | 2008-12-08 | 2015-10-13 | Philip Morris Usa Inc. | Soft, chewable and orally dissolvable and/or disintegrable products |
| US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| MX2013004364A (es) | 2010-10-19 | 2013-07-02 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
| EP2680859B1 (en) | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| US20180099001A1 (en) * | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| CA3008794C (en) | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| SI3150616T1 (sl) | 2012-11-16 | 2017-08-31 | University College Cardiff Consultants Limited | Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata |
| US20150352189A1 (en) * | 2013-01-08 | 2015-12-10 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| MX384232B (es) | 2013-03-14 | 2025-03-14 | Jerome J Schentag | Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. |
| JP2016516717A (ja) * | 2013-03-15 | 2016-06-09 | シーダーズ−サイナイ メディカル センター | メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法 |
| DK3107568T3 (da) * | 2014-02-20 | 2024-06-03 | Vaxart Inc | Formuleringer til indgivelse til tyndtarmen |
| WO2016011335A1 (en) * | 2014-07-17 | 2016-01-21 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
| EA201792512A1 (ru) | 2015-06-12 | 2018-06-29 | Вэксарт, Инк. | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник |
| US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
| CA2990230A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
| JP6894923B2 (ja) | 2016-04-11 | 2021-06-30 | ジェンフィＧｅｎｆｉｔ | 胆汁うっ滞性及び線維性の疾患の処置方法 |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| US11400078B2 (en) * | 2016-04-11 | 2022-08-02 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| WO2017203367A2 (en) * | 2016-05-22 | 2017-11-30 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| WO2018090049A1 (en) * | 2016-11-14 | 2018-05-17 | The Brigham And Women's Hospital, Inc. | Estrogen sensing through gper1 regulates normal and malignant liver growth |
| US11033534B2 (en) | 2017-01-27 | 2021-06-15 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018167103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| GB2571749A (en) * | 2018-03-07 | 2019-09-11 | Anabio Tech Limited | A method inducing satiety in a mammal |
| DK3666262T3 (da) | 2018-12-10 | 2022-01-31 | Aphaia Ip Ag | Farmaceutiske orale doseringsformer til behandling af stofskifteforstyrrelser og lignende sygdomme ved orkestreret frigivelse af enterokiner |
| WO2020120519A1 (en) | 2018-12-10 | 2020-06-18 | Aphaia Pharma Ag | Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines |
| CN109568284B (zh) * | 2018-12-29 | 2020-04-24 | 广东中润药物研发有限公司 | 一种替诺福韦艾拉酚胺肠溶片及其制备方法 |
| CN110478357A (zh) * | 2019-07-23 | 2019-11-22 | 哈尔滨医科大学 | 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2020452539A1 (en) | 2020-06-10 | 2023-02-02 | Aphaia Pharma Ag | Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| JP7109827B1 (ja) * | 2021-11-16 | 2022-08-01 | 株式会社ハニック・ホワイトラボ | 抗ウイルス剤 |
| WO2024049280A1 (ko) * | 2022-09-01 | 2024-03-07 | 주식회사 제노포커스 | 수퍼옥시드 디스뮤타제를 발현하는 바실러스 종 균주, 바실러스 종 균주 포자 및/또는 수퍼옥시드 디스뮤타제 및 이의 섬유화 질환 예방 또는 치료용 용도 |
| WO2025119939A1 (en) | 2023-12-03 | 2025-06-12 | Aphaia Pharma Ag | Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions |
| LU103233B1 (en) | 2023-12-21 | 2025-06-24 | Aphaia Ip Ag | Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions |
| WO2025235457A1 (en) | 2024-05-09 | 2025-11-13 | Alsteni Medical, Inc. | Intraoral gastrointestinal access device and related methods |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51133489A (en) * | 1975-05-14 | 1976-11-19 | Tokyo Daigaku | Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities |
| US4544550A (en) | 1982-10-05 | 1985-10-01 | Rodolfo Almanzor Y | Method for the treatment of diabetes |
| US5194464A (en) | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
| US5769793A (en) | 1989-09-08 | 1998-06-23 | Steven M. Pincus | System to determine a relative amount of patternness |
| US5120563A (en) * | 1989-12-21 | 1992-06-09 | The Procter & Gamble Company | Food compositions containing reduced calorie fats and reduced calorie sugars |
| DK0625204T3 (da) * | 1992-02-04 | 2002-07-15 | Chiron Corp | Terapeutiske midler mod hepatitis |
| US5322697A (en) | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
| US5976548A (en) | 1994-11-08 | 1999-11-02 | Viva America Marketing, Inc. | Nutritional supplement composition and use |
| CN1194831A (zh) * | 1997-04-01 | 1998-10-07 | 李春华 | 利巴韦林大输液系列制剂 |
| AU766597B2 (en) * | 1998-05-15 | 2003-10-16 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP5684964B2 (ja) | 2000-06-07 | 2015-03-18 | ワトソン ファーマシューティカルズ， インコーポレイテッド | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| WO2004000280A1 (en) | 2002-04-29 | 2003-12-31 | Shire Laboraties, Inc. | Pharmaceutical formulations with improved bioavailability |
| US20040062778A1 (en) * | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
| EP1462116A1 (en) | 2003-03-29 | 2004-09-29 | Villitech SARL | Composition for treating the gastrointestinal tract |
| WO2005110455A2 (en) | 2004-05-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating hepatitis virus infection |
| US7329419B2 (en) | 2004-09-23 | 2008-02-12 | Herbalife International, Inc. | Herbal supplement to support weight loss |
| JP2008514616A (ja) | 2004-09-24 | 2008-05-08 | メルク エンド カムパニー インコーポレーテッド | 肥満の治療のための組合せ療法 |
| US20060093592A1 (en) | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
| JP2008542380A (ja) * | 2005-05-31 | 2008-11-27 | ノバルティス アクチエンゲゼルシャフト | 鉄が病因に関与する肝臓疾患の処置 |
| JP2007001945A (ja) | 2005-06-24 | 2007-01-11 | Tsuneo Ozeki | 癌治療剤 |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| CN101291685A (zh) * | 2005-08-19 | 2008-10-22 | 安米林药品公司 | 治疗糖尿病和降低体重的毒蜥外泌肽 |
| WO2007029238A2 (en) | 2005-09-06 | 2007-03-15 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| US20100143481A1 (en) * | 2006-11-08 | 2010-06-10 | Dinesh Shenoy | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| US20070172525A1 (en) | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| US20110046053A1 (en) | 2008-05-05 | 2011-02-24 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
| WO2010027498A2 (en) * | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
| CA2740874C (en) | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| TWI460178B (zh) * | 2009-02-12 | 2014-11-11 | Arqule Inc | 組合性組成物及治療癌症之方法 |
| WO2010102041A2 (en) | 2009-03-04 | 2010-09-10 | Meyer Nutriceuticals, Llc | Composition and method for control of diabetes |
| RU2410108C1 (ru) | 2009-08-03 | 2011-01-27 | Государственное образовательное учреждение высшего профессионального образования "Орловский государственный технический университет" (ОрелГТУ) | Способ скармливания пробиотика поросятам-сосунам |
| US8999721B2 (en) | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US8367418B2 (en) | 2009-10-23 | 2013-02-05 | Therasyn Sensors, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| US20140294951A1 (en) | 2011-10-26 | 2014-10-02 | Joseph M. Fayad | Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D |
| EP2680859B1 (en) | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| CA3008794C (en) | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| US20150352189A1 (en) | 2013-01-08 | 2015-12-10 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
-
2012
- 2012-02-24 EP EP12752890.9A patent/EP2680859B1/en active Active
- 2012-02-24 KR KR1020207000460A patent/KR20200006177A/ko not_active Ceased
- 2012-02-24 KR KR1020187030127A patent/KR102198749B1/ko not_active Expired - Fee Related
- 2012-02-24 WO PCT/US2012/026561 patent/WO2012118712A2/en not_active Ceased
- 2012-02-24 CN CN201910281848.9A patent/CN110152000A/zh active Pending
- 2012-02-24 AU AU2012223528A patent/AU2012223528A1/en not_active Abandoned
- 2012-02-24 JP JP2013556750A patent/JP6253991B2/ja not_active Expired - Fee Related
- 2012-02-24 EA EA201391262A patent/EA201391262A1/ru unknown
- 2012-02-24 US US14/002,642 patent/US9370528B2/en active Active
- 2012-02-24 KR KR1020137026087A patent/KR20140147657A/ko not_active Ceased
- 2012-02-24 CN CN201280021792.XA patent/CN103635196B/zh not_active Expired - Fee Related
- 2012-02-24 KR KR1020197014958A patent/KR20190060879A/ko not_active Ceased
- 2012-02-24 BR BR112013022391A patent/BR112013022391A2/pt active Search and Examination
-
2013
- 2013-09-02 IL IL228259A patent/IL228259B/en active IP Right Grant
-
2016
- 2016-05-24 US US15/162,941 patent/US9730951B2/en active Active
-
2017
- 2017-04-25 AU AU2017202713A patent/AU2017202713A1/en not_active Abandoned
- 2017-06-15 US US15/624,275 patent/US10245277B2/en active Active
- 2017-11-29 JP JP2017228965A patent/JP2018065840A/ja active Pending
-
2018
- 2018-03-29 IL IL258450A patent/IL258450A/en unknown
-
2019
- 2019-02-27 JP JP2019033502A patent/JP2019123716A/ja active Pending
- 2019-03-20 AU AU2019201917A patent/AU2019201917A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506928A5 (https=) | ||
| JP6253991B2 (ja) | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 | |
| CN100536853C (zh) | β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 | |
| JP6360607B2 (ja) | ２つの抗ウイルス化合物の組合せ製剤 | |
| KR101962522B1 (ko) | 두 항바이러스 화합물의 병용 제형물 | |
| ES2661850T3 (es) | Moduladores de receptores del tipo toll | |
| US9415046B2 (en) | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods | |
| JP2013082726A (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| JP7617898B2 (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| US20260034191A1 (en) | Larazotide formulations | |
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| CA3139291A1 (en) | Method for decreasing adverse-effects of interferon | |
| JP2017536380A5 (https=) | ||
| WO2022142945A1 (zh) | 一种用于治疗或预防病毒性肝炎的药物组合物及其应用 | |
| WO2022213870A1 (zh) | 通过口服给药抑制CD4+Treg细胞的药物和方法 | |
| Sandmann et al. | HBV cure—The light at the end of the tunnel? | |
| HK40010279A (en) | Compositions for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection | |
| TW200811138A (en) | Pharmaceuticals | |
| HK1192143A (en) | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection | |
| HK1220392B (zh) | 两种抗病毒化合物的复方制剂 |